Corcept Therapeutics
Corcept Therapeutics
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | ACTH-dependent Cushing syndrome, Cushing syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland hyperfunction, brain disorder, carcinoma, cardiovascular disorder, central nervous system disorder, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, epithelial neoplasm, glucose metabolism disease, hyperpituitarism, hypertensive disorder, hypothalamic disorder, malignant endocrine neoplasm, metabolic disease, neoplasm, nervous system disorder, paraneoplastic syndrome, pituitary gland disorder, type 2 diabetes mellitus, vascular disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT03604198 | |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Recruiting | Phase 2 | 2026-09-25 | NCT07259317 | |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, peritoneal neoplasm | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05257408 | |
| Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05407324 | |
| Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT07276373 | |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, peritoneal neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-07-16 | NCT06906341 | |
| Evaluating the Pharmacokinetics and Safety of Miricorilant | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 1 | 2026-05-26 | NCT07553663 | |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-02-25 | NCT06099769 | |
| REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Recruiting | Phase 2 | 2024-11-14 | NCT06689254 |